Aller au contenu principal
2026 review

Global health status time to deterioration after systemic treatments of advanced gastric cancer: a systematic review and trial-level analysis

0Citations signalées — pas une note de qualité
2Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Objective Although health-related quality of life (HRQoL) endpoints have often demonstrated a benefit from treatments that have prolonged overall survival (OS), their relationship with OS and other clinical trial endpoints remains unclear. The study aims to conduct a systematic review of phase III trials assessing HRQoL, time-to-deterioration (TTD), and imaging-related endpoints in patients with advanced gastric cancer receiving systemic therapy.Methods A systematic review identified phase III trials reporting results of OS, TTD and imaging-related endpoints, such as progression-free survival (PFS) and objective response rate (ORR). From each trial the results of the four endpoints were extracted. An arm-level and a trial-level analysis were carried out.Results Sixteen articles were identified, reporting the results of HRQoL endpoint of 17 trials. From the trials complete data of 21 study arms and 15 trial-level comparisons were available. At the arm-level analysis, all the endpoints reported a significant correlation with OS. The trial-level analysis documented a consistent relationship of treatment effects between PFS and OS (R2=0.313; β = 0.174; p-value = 0.030), but not between ORR and OS and between TTD and OS.Conclusion None of the endpoints examined can be considered a surrogate for OS, although PFS remains the variable that correlates most closely with OS in the trial-level analysis. The TTD of the EORTC-QLQ-C30 GHS subscale requires standardization and subsequent prospective and retrospective re-evaluation as a surrogate endpoint. However, it warrants greater attention in future studies as a co-primary or secondary outcome, as it could provide additional and clinically relevant information compared with imaging-related outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Global health status time to deterioration after systemic treatments of advanced gastric cancer: a systematic review and trial-level analysis
Date Crossref
27/08/2026
Éditeur
Informa UK Limited
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Gastric Cancer Management and OutcomesEsophageal Cancer Research and TreatmentLung Cancer Diagnosis and Treatment

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.